Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA’s move away from reliance on animal testing towards organoid, organ-on-a-chip, and other in silico technologies. A Connecticut startup believes whole-organ testing should be an essential part of this mix.
The post Organ-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On It appeared first on MedCity News.
